MAPK3 and type 2 diabetes mellitus: However, inhibition of both signalling pathways, JAK/STAT and MAPK/ERK1,2, with ruxolitinib and trametinib, respectively, caused a significant reduction in the generation of mROS in HSVSMCs from both T2DM and non-diabetic patients.